Catalyst Wire Dossier Catalyst Wire Dossier

Rebecsinib

rebecsinib · Aspera Biomedicines, Inc.
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Rebecsinib, covering 2026-01-27 to 2026-01-27. Get the full timeline:

Most recent: Clinical Trial Update: A Study of Rebecsinib for Patients With Relapsed/Refractory Secondary Acute Myeloid Leukemia or High Risk Myelofibrosis [Phase 1]

See pricing